Condition

HR+/HER2- Ductal and Lobular Breast Cancer clinical trials and research

• 2Clinical trials
• 12Countries

All recruiting trials (2)

• Targeted radioligand [177Lu]Lu-DFC413 for advanced pancreatic, lung, breast, and colorectal cancers

  This will test a new targeted radioactive medicine, [177Lu]Lu-DFC413 (with a PET tracer [68Ga]Ga-NNS309), to see if it is safe and shows activity in adults with advanced pancreatic, lung, breast, or colorectal cancer.

  Recruiting at 9 sites Phase 1 Novartis · Princeton, New Jersey and 8 other locations · NCT07261631

• Evaluating a new treatment for advanced pancreatic, lung, breast, and colorectal cancers

  This study is testing a new type of radiation treatment for people with advanced pancreatic, lung, breast, and colorectal cancers to see if it is safe and effective.

  Recruiting at 29 sites Phase 1 Novartis · Birmingham, Alabama and 28 other locations · NCT06562192

Related topics

Quick answers

How many HR+/HER2- Ductal and Lobular Breast Cancer clinical trials are recruiting right now?

2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 12 countries. The most sites are in Canada (2 trials), France (2 trials), Germany (2 trials), Israel (2 trials), United States (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →